NEW YORK (GenomeWeb) – Admera Health today announced that its PGxOne Plus and OncoGxOne molecular diagnostic tests have been approved for clinical use by the New Jersey Department of Health.

PGxOne is a companion diagnostic test to help predict response to therapy based on the patients' genetics. The gene panel, which assays 25 genes known to determine drug response, is an expanded version of Admera's PGxOne test.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.